Anti-Human ErbB2/Her2 Reference Antibody (BSI-001, RUO) (HY286296)

Name: Anti-Human ErbB2/Her2 Reference Antibody (BSI-001, RUO)
Brand: abinScience
SKU: HY286296
Price: 370 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号	HY286296
種反応性	Human
アプリケーション	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
宿主種	Human
クローン性	Monoclonal
アイソタイプ	IgG
クローンID	BSI-001
生物学的活性	BSI-001 binds strongly to BT-474 and SK-BR-3 cells with overexpressed HER2 [1]. BSI-001 (100 nM, serially diluted; 3-6 days) exerts weak inhibitory effects on the proliferation of HER2-positive cancer cells when used alone, but it exerts potent synergistic anti-proliferative effects in multiple HER2-positive cancer cell lines when combined with Trastuzumab () at a fixed dose ratio of 1:1 [1]. BSI-001 (72 h) potently inhibits the migration of BT-474 cells when combined with Trastuzumab [1]. BSI-001 (100 nM; 72 h) = induces late-stage apoptosis and PARP cleavage in BT-474 cells when combined with Trastuzumab [1]. BSI-001 (100 nM; 3 days) reduces the total HER2 protein level in BT-474 cells and inhibits HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, HER3, AKT and ERK) when combined with Trastuzumab [1]. . In combination with Trastuzumab, showed substantially enhanced BT-474 cell proliferation inhibition compared to single agents. Showed stronger synergism between 5G9 and trastuzumab. In SK-BR-3, AU-565, and NCI-N87 cells, the combination of 5G9 and trastuzumab reduced cell viability more effectively. Apoptosis Analysis [1] Cell Line: HER2-positive human breast cancer BT-474 cells Concentration: 100 nM Incubation Time: 72 h Result: Resulted in a significantly lower number of viable BT-474 cells and a higher level of late-stage apoptosis combinated with Trastuzumab, compared to the trastuzumab-pertuzumab combination.
ターゲット	CD340, EC:2.7.10.1, ERBB2, HER2, MLN 19, MLN19, Metastatic lymph node gene 19 protein, NEU, NGL, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2
エンドトキシンレベル	< 10 EU/mg
純度	>95% as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	P04626
形態	Liquid
保存バッファー	0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名	BSI-001, BSI001, BSI001
背景	Receptor tyrosine-protein kinase erbB-2 (CD340/ERBB2) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. CD340 is the therapeutic target of trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu).
参考文献	1. Ding X, et al. A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity. EBioMedicine. 2020 Oct;60:102996. [HY286296]
注意事項	For research use only. Not suitable for clinical or therapeutic use.